223 related articles for article (PubMed ID: 24381243)
1. Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
Saraceni MM; Venci JV; Gandhi MA
J Pharm Pract; 2014 Aug; 27(4):389-95. PubMed ID: 24381243
[TBL] [Abstract][Full Text] [Related]
2. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
3. The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.
Bruno A; Morabito P; Spina E; Muscatello MR
Curr Neuropharmacol; 2016; 14(2):191-9. PubMed ID: 26572745
[TBL] [Abstract][Full Text] [Related]
4. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
5. Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
Mago R; Mahajan R; Thase ME
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):137-45. PubMed ID: 24524592
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
Sambunaris A; Gommoll C; Chen C; Greenberg WM
Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
[TBL] [Abstract][Full Text] [Related]
7. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Scott LJ
CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
[TBL] [Abstract][Full Text] [Related]
8. Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.
Chen L; Greenberg WM; Gommoll C; O'Connor J; Zukin SR; Periclou A; Ghahramani P
Clin Ther; 2015 Sep; 37(9):2059-70. PubMed ID: 26256429
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of levomilnacipran extended release in treating major depressive disorder.
Ragguett RM; Yim SJ; Ho PT; McIntyre RS
Expert Opin Pharmacother; 2017 Dec; 18(18):2017-2024. PubMed ID: 29195487
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
Blum SI; Tourkodimitris S; Ruth A
J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
[TBL] [Abstract][Full Text] [Related]
11. Levomilnacipran extended release: first global approval.
Hair P; Cameron F; Garnock-Jones KP
Drugs; 2013 Sep; 73(14):1639-45. PubMed ID: 24000002
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.
Mago R; Forero G; Greenberg WM; Gommoll C; Chen C
Clin Drug Investig; 2013 Oct; 33(10):761-71. PubMed ID: 23999912
[TBL] [Abstract][Full Text] [Related]
14. Levomilnacipran (Fetzima) a new SNRI for depression.
Med Lett Drugs Ther; 2013 Dec; 55(1432):101-2. PubMed ID: 24419243
[No Abstract] [Full Text] [Related]
15. Safety and Efficacy of Levomilnacipran Extended Release in Pediatric Patients Aged 7-17 Years with Major Depressive Disorder: Results of Two Phase 3, Randomized, Double-Blind Studies.
Radecki DT; Robieson WZ; Gopalkrishnan M; Greenberg E; Aziz M
J Child Adolesc Psychopharmacol; 2024 Jun; 34(5):241-250. PubMed ID: 38700708
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
[TBL] [Abstract][Full Text] [Related]
17. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
[TBL] [Abstract][Full Text] [Related]
18. A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633).
Asnis GM; Caneva E; Henderson MA
Expert Opin Drug Saf; 2016 May; 15(5):717-25. PubMed ID: 26967743
[TBL] [Abstract][Full Text] [Related]
19. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Ishigooka J
Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
[TBL] [Abstract][Full Text] [Related]
20. Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1.
Rizvi SM; Shaikh S; Khan M; Biswas D; Hameed N; Shakil S
CNS Neurol Disord Drug Targets; 2014; 13(8):1427-31. PubMed ID: 25345508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
